TP53 and diffuse large B-cell lymphoma: Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.